Related Experiment Video

Updated: Aug 20, 2026

Inducible and Reversible Dominant-negative (DN) Protein Inhibition
08:35

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Published on: January 7, 2019

Expression and amplification of therapeutic target genes in retinoblastoma

Doris Bösch1, Mona Pache, Ronald Simon

  • 1Universitäts-Augenklinik Basel, Mittlere Strasse 91, 4056, Basel, Switzerland.

Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie
|November 19, 2004
PubMed
Abstract

Insights

This study investigated KIT (CD 117), EGFR, and HER-2 alterations in retinoblastoma. Some retinoblastoma cases show potential for targeted therapies like anti-EGFR and imatinib mesylate.

Area of Science:

  • Oncology
  • Molecular Biology
  • Ophthalmology

Background:

  • Retinoblastoma is a pediatric eye cancer.
  • Identifying therapeutic targets is crucial for improving patient outcomes.
  • Specific gene alterations may predict treatment response.

Purpose of the Study:

  • To evaluate the expression and alterations of KIT (CD 117), EGFR, and HER-2 in human retinoblastoma.
  • To determine the potential of these genes as therapeutic targets.

Main Methods:

  • Analysis of 95 retinoblastoma tumor samples using tissue microarrays.
  • Immunohistochemistry to assess CD117, EGFR, and HER-2 expression.
  • Fluorescence in situ hybridization (FISH) for EGFR amplification detection.
  • Sanger sequencing of KIT exon 11 in CD117-positive tumors.

Main Results:

  • CD117 expression was detected in 19% of cases, with no KIT mutations found.
  • EGFR was expressed in 14% of cases, but no EGFR amplification was observed.
  • All tested retinoblastoma samples were negative for HER-2 expression.

Conclusions:

  • The findings suggest that retinoblastoma may respond to therapies targeting EGFR.
  • Imatinib mesylate (STI571) could be a potential therapeutic option for selected retinoblastoma cases.
  • Further investigation into these genetic alterations could guide personalized treatment strategies.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...